与吲哚美辛治疗动脉导管未闭失败有关。
is associated with indomethacin treatment failure for patent ductus arteriosus.
机构信息
Vanderbilt University School of Medicine, UCSF, Nashville, TN 37232, USA.
Department of Pediatrics, Vanderbilt University Medical Center, UCSF, Nashville, TN 37232, USA.
出版信息
Pharmacogenomics. 2019 Aug;20(13):939-946. doi: 10.2217/pgs-2019-0079.
Abstract
To identify clinical andgenetic factors associated with indomethacin treatment failure in preterm neonates with patent ductus arteriosus (PDA). This is a multicenter cohort study of 144 preterm infants (22-32 weeks gestational age) at three centers who received at least one treatment course of indomethacin for PDA. Indomethacin failure was defined as requiring subsequent surgical intervention. In multivariate analysis, gestational age (AOR 0.76, 95% CI 0.60-0.96), surfactant use (AOR 9.77, 95% CI 1.15-83.26), and (AOR 3.74; 95% CI 1.34-10.44) were each associated with indomethacin failure. Age, surfactant use, and influence indomethacin treatment outcome in preterm infants with PDA. This combination of clinical and genetic factors may facilitate targeted indomethacin use for PDA.
摘要
目的
确定与早产儿动脉导管未闭（PDA）接受吲哚美辛治疗失败相关的临床和遗传因素。 这是一项在三个中心进行的 144 例早产儿（胎龄 22-32 周）的多中心队列研究，这些早产儿接受了至少一个疗程的吲哚美辛治疗 PDA。吲哚美辛治疗失败定义为需要后续手术干预。 在多变量分析中，胎龄（AOR 0.76，95%CI 0.60-0.96）、表面活性剂使用（AOR 9.77，95%CI 1.15-83.26）和（AOR 3.74；95%CI 1.34-10.44）均与吲哚美辛治疗失败相关。 年龄、表面活性剂使用和基因型均影响早产儿 PDA 中吲哚美辛的治疗效果。这些临床和遗传因素的组合可能有助于针对 PDA 进行有针对性的吲哚美辛治疗。
相似文献
1
is associated with indomethacin treatment failure for patent ductus arteriosus.与吲哚美辛治疗动脉导管未闭失败有关。
Pharmacogenomics. 2019 Aug;20(13):939-946. doi: 10.2217/pgs-2019-0079.
2
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants.环氧化酶抑制剂用于早产儿有症状动脉导管未闭的手术治疗与药物治疗对比
Cochrane Database Syst Rev. 2008 Jan 23(1):CD003951. doi: 10.1002/14651858.CD003951.pub2.
3
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.布洛芬用于治疗早产和/或低出生体重婴儿的动脉导管未闭。
Cochrane Database Syst Rev. 2008 Jan 23(1):CD003481. doi: 10.1002/14651858.CD003481.pub3.
4
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants.环氧化酶抑制剂用于早产儿症状性动脉导管未闭的手术治疗与药物治疗对比
Cochrane Database Syst Rev. 2003(3):CD003951. doi: 10.1002/14651858.CD003951.
5
Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.布洛芬用于治疗早产或低出生体重（或两者兼具）婴儿的动脉导管未闭。
Cochrane Database Syst Rev. 2015 Feb 18(2):CD003481. doi: 10.1002/14651858.CD003481.pub6.
6
Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.布洛芬用于治疗早产或低出生体重（或两者兼具）婴儿的动脉导管未闭。
Cochrane Database Syst Rev. 2018 Sep 28;9(9):CD003481. doi: 10.1002/14651858.CD003481.pub7.
7
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.布洛芬用于治疗早产和/或低出生体重婴儿的动脉导管未闭。
Cochrane Database Syst Rev. 2005 Oct 19(4):CD003481. doi: 10.1002/14651858.CD003481.pub2.
8
Polymorphisms in CYP2C9 are associated with response to indomethacin among neonates with patent ductus arteriosus.CYP2C9 基因多态性与动脉导管未闭新生儿对吲哚美辛反应的相关性。
Pediatr Res. 2017 Nov;82(5):776-780. doi: 10.1038/pr.2017.145. Epub 2017 Jul 5.
9
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.对乙酰氨基酚（醋氨酚）用于早产儿或低出生体重儿动脉导管未闭的治疗。
Cochrane Database Syst Rev. 2020 Jan 27;1(1):CD010061. doi: 10.1002/14651858.CD010061.pub4.
10
Indomethacin for symptomatic patent ductus arteriosus in preterm infants.吲哚美辛治疗早产儿症状性动脉导管未闭。
Cochrane Database Syst Rev. 2021 Jan 15;1(1):CD013133. doi: 10.1002/14651858.CD013133.pub2.
引用本文的文献
1
Association between endotypes of prematurity and pharmacological closure of patent ductus arteriosus: A systematic review and meta-analysis.早产内型与动脉导管未闭药物闭合之间的关联：一项系统评价和荟萃分析。
Front Pediatr. 2023 Mar 3;11:1078506. doi: 10.3389/fped.2023.1078506. eCollection 2023.
2
Patent Ductus Arteriosus: A Contemporary Perspective for the Pediatric and Adult Cardiac Care Provider.动脉导管未闭：儿科和成人心脏护理提供者的当代视角。
J Am Heart Assoc. 2022 Sep 6;11(17):e025784. doi: 10.1161/JAHA.122.025784. Epub 2022 Sep 3.
3
Sex Differences in Patent Ductus Arteriosus Incidence and Response to Pharmacological Treatment in Preterm Infants: A Systematic Review, Meta-Analysis and Meta-Regression.早产儿动脉导管未闭发病率及药物治疗反应的性别差异：一项系统评价、荟萃分析和元回归分析
J Pers Med. 2022 Jul 14;12(7):1143. doi: 10.3390/jpm12071143.
4
The Impact of Pharmacogenetics on Pharmacokinetics and Pharmacodynamics in Neonates and Infants: A Systematic Review.药物遗传学对新生儿和婴儿药代动力学及药效学的影响：一项系统评价
Pharmgenomics Pers Med. 2022 Jun 30;15:675-696. doi: 10.2147/PGPM.S350205. eCollection 2022.
5
Mouse models of patent ductus arteriosus (PDA) and their relevance for human PDA.动脉导管未闭（PDA）的小鼠模型及其与人类 PDA 的相关性。
Dev Dyn. 2022 Mar;251(3):424-443. doi: 10.1002/dvdy.408. Epub 2021 Aug 14.
6
Molecular Mechanisms Underlying Remodeling of Ductus Arteriosus: Looking beyond the Prostaglandin Pathway.动脉导管重塑的分子机制：超越前列腺素途径的研究。
Int J Mol Sci. 2021 Mar 22;22(6):3238. doi: 10.3390/ijms22063238.
7
Patent Ductus Arteriosus of the Preterm Infant.早产儿动脉导管未闭。
Pediatrics. 2020 Nov;146(5). doi: 10.1542/peds.2020-1209.
本文引用的文献
1
Covariation of Neonatal Intensive Care Unit-Level Patent Ductus Arteriosus Management and In-Neonatal Intensive Care Unit Outcomes Following Preterm Birth.新生儿重症监护病房级别动脉导管未闭管理与早产儿出生后新生儿重症监护病房内结局的相关性。
J Pediatr. 2018 Dec;203:225-233.e1. doi: 10.1016/j.jpeds.2018.07.025. Epub 2018 Sep 20.
2
Patent ductus arteriosus, its treatments, and the risks of pulmonary morbidity.动脉导管未闭、其治疗方法以及肺部发病风险。
Semin Perinatol. 2018 Jun;42(4):235-242. doi: 10.1053/j.semperi.2018.05.006. Epub 2018 May 10.
3
Changing patterns of patent ductus arteriosus surgical ligation in the United States.美国动脉导管未闭手术结扎模式的变化。
Semin Perinatol. 2018 Jun;42(4):253-261. doi: 10.1053/j.semperi.2018.05.008. Epub 2018 May 22.
4
Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.动脉导管未闭（PDA）的遗传学和 PDA 治疗的药物遗传学。
Semin Fetal Neonatal Med. 2018 Aug;23(4):232-238. doi: 10.1016/j.siny.2018.02.006. Epub 2018 Feb 24.
5
Predictors of PDA Treatment in Preterm Neonates Who Had Received Prophylactic Indomethacin.接受预防性吲哚美辛治疗的早产儿动脉导管未闭治疗的预测因素。
Am J Perinatol. 2018 Apr;35(5):509-514. doi: 10.1055/s-0037-1608792. Epub 2017 Nov 28.
6
Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants.药物性闭合胎龄小的极早产儿动脉导管未闭的疗效
Early Hum Dev. 2017 Oct;113:10-17. doi: 10.1016/j.earlhumdev.2017.07.011. Epub 2017 Jul 8.
7
Polymorphisms in CYP2C9 are associated with response to indomethacin among neonates with patent ductus arteriosus.CYP2C9 基因多态性与动脉导管未闭新生儿对吲哚美辛反应的相关性。
Pediatr Res. 2017 Nov;82(5):776-780. doi: 10.1038/pr.2017.145. Epub 2017 Jul 5.
8
Trends and variation in management and outcomes of very low-birth-weight infants with patent ductus arteriosus.极低出生体重动脉导管未闭婴儿的管理及结局的趋势与差异
Pediatr Res. 2016 Dec;80(6):785-792. doi: 10.1038/pr.2016.166. Epub 2016 Aug 10.
9
Surgical ligation of patent ductus arteriosus in premature infants: trends and practice variation.早产儿动脉导管未闭的手术结扎：趋势与实践差异
Cardiol Young. 2016 Aug;26(6):1107-14. doi: 10.1017/S1047951115001869. Epub 2015 Sep 23.
10
Comparative effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus.吲哚美辛与布洛芬治疗动脉导管未闭的疗效及安全性比较
Early Hum Dev. 2015 Dec;91(12):725-9. doi: 10.1016/j.earlhumdev.2015.08.003. Epub 2015 Sep 19.
Zotero 插件